GLANCE

Rating neurologic impairment in multiple sclerosis

1983 • 14,011 citations

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

2001 • 6,888 citations

Defining the clinical course of multiple sclerosis

1996 • 3,606 citations

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 • 3,172 citations

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

1996 • 2,410 citations

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1998 • 2,049 citations

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

1993 • 2,032 citations

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

1995 • 1,903 citations

Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin

1992 • 1,711 citations

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 • 1,289 citations

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2003 • 1,228 citations

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma.

1993 • 837 citations

Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy

2006 • 794 citations

Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

2000 • 412 citations

Anti-α4 integrin therapy for multiple sclerosis

2005 • 287 citations

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1997 • 280 citations

Pathogenesis of multiple sclerosis

1994 • 230 citations

Natalizumab effects on immune cell responses in multiple sclerosis

2006 • 206 citations

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1998 • 176 citations

Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS

2004 • 157 citations

A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis

2002 • 55 citations

During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4

2006 • 40 citations

Glatiramer acetate immunization induces specific antibody and cytokine responses in ALS patients

2007 • 20 citations